Jing Li
Founder and CEO VelaVigo
Seminars
Tuesday 9th March 2027
Showcasing Phase 1/2a Open-Label Clinical Trial Results Evaluating VBC103, a Nectin-4 & TROP2 Targeted Bi-Specific ADC in Participants with Advanced Solid Tumour Malignancies
5:15 pm
- Leveraging an internal R&D engine for consistent delivery of ADC programmes
- Designing a novel dual-targeting bispecific ADC that simultaneously targets Nectin-4 and TROP2
- Showcasing Phase 1/2a open-label clinical trial results evaluating VBC103 in participants with advanced solid tumour malignancies
